These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9311590)

  • 1. Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening.
    Persson I; Thurfjell E; Bergstrom R; Holmberg L
    Int J Cancer; 1997 Sep; 72(5):758-61. PubMed ID: 9311590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.
    Persson I; Yuen J; Bergkvist L; Schairer C
    Int J Cancer; 1996 Jul; 67(3):327-32. PubMed ID: 8707404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
    Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
    JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined hormone replacement therapy and risk of breast cancer in a French cohort study of 3175 women.
    de Lignières B; de Vathaire F; Fournier S; Urbinelli R; Allaert F; Le MG; Kuttenn F
    Climacteric; 2002 Dec; 5(4):332-40. PubMed ID: 12626212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postmenopausal estrogen-containing hormone therapy and the risk of breast cancer.
    Jick SS; Hagberg KW; Kaye JA; Jick H
    Obstet Gynecol; 2009 Jan; 113(1):74-80. PubMed ID: 19104362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
    Olsson HL; Ingvar C; Bladström A
    Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of patterns of hormone replacement therapy use and mammographic density on breast cancer detection.
    Chiarelli AM; Kirsh VA; Klar NS; Shumak R; Jong R; Fishell E; Yaffe MJ; Boyd NF
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1856-62. PubMed ID: 17035392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of breast cancer after estrogen and estrogen-progestin replacement.
    Bergkvist L; Adami HO; Persson I; Hoover R; Schairer C
    N Engl J Med; 1989 Aug; 321(5):293-7. PubMed ID: 2546079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.
    Prescrire Int; 2004 Jun; 13(71):106-9. PubMed ID: 15233153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K
    Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen and estrogen-progestin replacement therapy and risk of postmenopausal breast cancer in Canada.
    Kirsh V; Kreiger N
    Cancer Causes Control; 2002 Aug; 13(6):583-90. PubMed ID: 12195648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators.
    Greendale GA; Reboussin BA; Sie A; Singh HR; Olson LK; Gatewood O; Bassett LW; Wasilauskas C; Bush T; Barrett-Connor E
    Ann Intern Med; 1999 Feb; 130(4 Pt 1):262-9. PubMed ID: 10068383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial cancer and hormone-replacement therapy in the Million Women Study.
    Beral V; Bull D; Reeves G;
    Lancet; 2005 Apr 30-May 6; 365(9470):1543-51. PubMed ID: 15866308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
    Schairer C; Lubin J; Troisi R; Sturgeon S; Brinton L; Hoover R
    JAMA; 2000 Jan; 283(4):485-91. PubMed ID: 10659874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for in situ breast cancer.
    Longnecker MP; Bernstein L; Paganini-Hill A; Enger SM; Ross RK
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):961-5. PubMed ID: 8959317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of endometrial cancer following estrogen replacement with and without progestins.
    Weiderpass E; Adami HO; Baron JA; Magnusson C; Bergström R; Lindgren A; Correia N; Persson I
    J Natl Cancer Inst; 1999 Jul; 91(13):1131-7. PubMed ID: 10393721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidences of breast cancer throughout long-term hormone replacement therapy.
    Cortés-Prieto J; Juez-Martel P
    J Steroid Biochem Mol Biol; 2007 May; 104(3-5):180-9. PubMed ID: 17467269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen-progestin replacement therapy and breast cancer risk: the Women's Health Study (United States).
    Porch JV; Lee IM; Cook NR; Rexrode KM; Burin JE
    Cancer Causes Control; 2002 Nov; 13(9):847-54. PubMed ID: 12462550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.